Biomarker expression and IPI category distribution in all patients with DLBCL
| Biomarker expression* . | No. of patients with biomarker scored and IPI† . | No. of patients with biomarker expression (%) . | Biomarker expression percentage by IPI categories . | Adjusted χ2P‡ . | |||
|---|---|---|---|---|---|---|---|
| Low . | Low/intermediate . | High/intermediate . | High . | ||||
| BCL2 > 75% | 1279 | 630 (49%) | 39 | 50 | 58 | 63 | < .0001 |
| BCL6 staining | 965 | 842 (87%) | 91 | 85 | 83 | 86 | NS |
| CD10 staining | 1316 | 558 (42%) | 49 | 43 | 35 | 37 | .008 |
| CD5 > 75% | 1339 | 115 (9%) | 7 | 10 | 9 | 10 | NS |
| HLA-DR staining | 1348 | 1180 (88%) | 91 | 89 | 84 | 82 | .04 |
| Ki67 > 75% | 1119 | 627 (56%) | 61 | 48 | 52 | 60 | .04 |
| MUM1 > 75% | 1225 | 264 (22%) | 20 | 20 | 25 | 26 | NS |
| GCB/non-GCB§ (adjusted) | 1046 | 709 (68%) | 72 | 67 | 61 | 66 | NS |
| GCB/non-GCB§ (LLBC) | 1046 | 828 (79%) | 83 | 79 | 72 | 79 | NS |
| Biomarker expression* . | No. of patients with biomarker scored and IPI† . | No. of patients with biomarker expression (%) . | Biomarker expression percentage by IPI categories . | Adjusted χ2P‡ . | |||
|---|---|---|---|---|---|---|---|
| Low . | Low/intermediate . | High/intermediate . | High . | ||||
| BCL2 > 75% | 1279 | 630 (49%) | 39 | 50 | 58 | 63 | < .0001 |
| BCL6 staining | 965 | 842 (87%) | 91 | 85 | 83 | 86 | NS |
| CD10 staining | 1316 | 558 (42%) | 49 | 43 | 35 | 37 | .008 |
| CD5 > 75% | 1339 | 115 (9%) | 7 | 10 | 9 | 10 | NS |
| HLA-DR staining | 1348 | 1180 (88%) | 91 | 89 | 84 | 82 | .04 |
| Ki67 > 75% | 1119 | 627 (56%) | 61 | 48 | 52 | 60 | .04 |
| MUM1 > 75% | 1225 | 264 (22%) | 20 | 20 | 25 | 26 | NS |
| GCB/non-GCB§ (adjusted) | 1046 | 709 (68%) | 72 | 67 | 61 | 66 | NS |
| GCB/non-GCB§ (LLBC) | 1046 | 828 (79%) | 83 | 79 | 72 | 79 | NS |
The number of the 1514 patients scored for BCL2, BCL6, CD5, CD10, HLA-DR, Ki67, MUM1, GCB (adjusted), and GCB (LLBC) are 1306, 985, 1366, 1344, 1377, 1138, 1249, 1067, and 1067, respectively.
The number of additional patients without IPI for BCL2, BCL6, CD5, CD10, HLA-DR, Ki67, MUM1, GCB (adjusted), and GCB (LLBC) are 27, 20, 18, 27, 29, 19, 24, 21, and 21, respectively.
χ2P values are adjusted for 9 multiple comparisons
Among the 1046 patients scored using the adjusted GCB algorithm and with complete IPI data, 558 were CD10+ (GCB), 151 were CD10−/BCL6+/MUM1-(GCB), 242 were CD10−/BCL6+/MUM1+ (non-GCB), and 95 were CD10−/BCL6− (non-GCB). Among the 1046 patients scored using the LLBC GCB algorithm and with complete IPI data, 558 were CD10+ (GCB), 270 were CD10−/BCL6+/MUM1− (GCB), 123 were CD10−/BCL6+/MUM1+ (non-GCB), and 95 were CD10−/BCL6− (non-GCB).
NS indicates nonsignificant.